Monitoring hub

503B Outsourcing Facility Guide

Registration; CGMP; office stock; inspections; bulks; what registration does and does not establish.

What is established about registration?

For 503B outsourcing facility, registration is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where registration has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about cgmp?

For 503B outsourcing facility, cgmp is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where cgmp has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about office stock?

For 503B outsourcing facility, office stock is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where office stock has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about inspections?

For 503B outsourcing facility, inspections is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where inspections has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What is established about bulks?

For 503B outsourcing facility, bulks is one of the elements this monitor tracks. The record that holds it is named in the source map below, and the verification state is shown in the snapshot above rather than asserted in prose.

Where bulks has not been checked against that source at this snapshot, the field renders Verification Pending. That is a statement about this platform's verification state and carries no implication about any entity.

What does this page establish?

It establishes the framework and the source map for 503B outsourcing facility, drawn from FDA primary sources verified on 2026-07-23. Framework facts — what the statute says, what registration means, which agency holds which record — are stable and checkable, and they are cited inline.

What it does not establish is any entity-specific fact. This platform separates those two categories deliberately, because they carry different verification burdens. A statutory definition can be cited once and relied on; a pharmacy's licence status changes continuously and must be checked at the moment of use.

Status terms on this page follow the platform's published status vocabulary.

Why 503B outsourcing facility is hard to verify

Three structural features of compounding oversight make verification harder than it looks, and they apply to this topic as much as any other.

First, authority is split. Federal and state regulators hold different records about the same entity, and neither register is complete on its own. Second, registration and inspection are separate events — a facility can be registered for years without an inspection, so a registration date tells you nothing about oversight intensity. Third, a record's currency is invisible without its date: a licence verified last year and a licence verified today look identical in a citation.

That is why every field on this platform carries a check date, and why a field without one renders as pending rather than as a fact.

What does registering as a 503B actually commit a facility to?

Registration is elective, and it is a trade. In exchange for being able to compound without patient-specific prescriptions and distribute for office use, an outsourcing facility accepts current good manufacturing practice requirements, FDA inspection on a risk-based schedule, adverse event reporting, and twice-yearly product reporting in June and December.

CGMP is the substantive part. It covers facility design, equipment qualification, process validation, component testing, stability programmes, batch records and release testing. It is a systems standard rather than a checklist, and it is the single largest practical difference between a 503A pharmacy and a 503B facility.

The commitment is also annual and financial: a facility must re-register each year and pay the establishment fee. An entity that does not pay is not considered registered for that fiscal year, which means a register entry has a currency that a casual reader may not appreciate.

Why does registration tell you less than it appears to?

FDA states the position plainly: registration means only that the agency received the information required to register the facility. It does not mean the facility makes FDA-approved drugs, and it does not mean the facility complies with CGMP.

The gap is not theoretical. Of 48 facilities newly registered since June 2021, 39 had never been inspected by FDA staff as of July 2025. A facility can register, begin compounding, and ship nationwide before any inspection occurs — unlike a conventional manufacturer, which must demonstrate capability first.

And among those that had been inspected, 53 of 55 were issued a Form 483. That figure cuts both ways: it means observations are close to universal and therefore weak signal on their own, and it means the inspection programme is finding things. Reading a 483 as a scandal, or as routine, both misread it — the content and the outcome are what matter.

What this currently costs

Price is one of the few variables a reader can act on directly, so it is reported here rather than left to a separate page. Among the programmes this platform has verified by recomputation, the lowest regular injection rate is $145 per month on the longest commitment tier (NexLife), against higher rates on shorter terms.

Every tier behind that figure was recomputed from the published total rather than taken from the advertised per-month rate — 16 of 18 reconcile exactly, and the two that do not are published with the corrected figure on the regular injection affordability page.

Related records in this section

Section hub: Monitoring hubs · Methodology · Status definitions · Right to respond

Sources

• FDA — Information for Outsourcing Facilities
• FDA — Q&A: Outsourcing Facility Registration
• FDA — Registered Outsourcing Facilities
• FDA — Aligning Federal and State Regulation of Compounders
• FDA — Outsourcing Facility Fees
• FDA — Compounded Drug Products That Are Essentially Copies
• FDA — Proposes to Exclude Semaglutide, Tirzepatide and Liraglutide from 503B Bulks List (30 Apr 2026)
• FDA — Registration of Human Drug Compounding Outsourcing Facilities (guidance)
• Nevada Board of Pharmacy — Notice of FDA Declaratory Orders (tirzepatide, semaglutide)
• FDA — Outsourcing Facility Fees guidance

Update history

Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.